Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.3% – Here’s Why

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price was down 6.3% on Friday . The company traded as low as $26.70 and last traded at $27.0610. Approximately 3,162,114 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 30,509,105 shares. The stock had previously closed at $28.87.

Analyst Ratings Changes

A number of equities analysts recently weighed in on HIMS shares. UBS Group set a $23.00 price target on Hims & Hers Health in a research report on Friday, May 22nd. Leerink Partners increased their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Truist Financial increased their price target on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Barclays increased their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Finally, TD Cowen decreased their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Stock Performance

The firm has a 50 day moving average of $25.27 and a 200-day moving average of $26.83. The stock has a market capitalization of $6.26 billion, a PE ratio of -300.69, a P/E/G ratio of 52.12 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.20 earnings per share. Research analysts forecast that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 9,463 shares of the stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the sale, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This represents a 3.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,950 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at approximately $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 212,807 shares of company stock valued at $5,473,644 in the last 90 days. Insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after purchasing an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth about $30,000. EverSource Wealth Advisors LLC raised its stake in shares of Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after purchasing an additional 687 shares in the last quarter. Amundi raised its stake in shares of Hims & Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after purchasing an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Hims & Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after purchasing an additional 29,471 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.